Intravenous immune globulin removed from world market.
D004340:Drug Contamination; D004345:Drug Industry; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration
D016756:Immunoglobulins, Intravenous